AJMC® in the Press, September 25, 2026

The article, "FDA Panel Backs 6 Peptides for Compounding," published on AJMC.com, the website of The American Journal of Managed Care^® (AJMC^®), reported that the FDA's Pharmacy Compounding Advisory Committee narrowly recommended 6 of 7 reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon) for the 503A Bulks List, overriding career scientists who had opposed adding any of them, while rejecting the seventh, emideltide.

Streamline's "FDA weighs peptide ruling as critics warn of consumer scams" draws on AJMC's reporting for its factual foundation, citing it for the specific vote tallies, the evidence gaps FDA reviewers identified in the underlying peptide studies, and the scrutiny facing the reconstituted panel's composition, before layering in a MarketWatch cardiologist's warning that legalized compounding could fuel telehealth-driven consumer scams.